Consolidation and Conviction: H2 2025 Market Normalization

China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. While early-stage deal volume cooled, strategic liquidity remained robust for assets with mature clinical data or specialized modalities like ADCs and RDCs. Total disclosed financing for the final months of the year reached approximately US$ 1.02 billion, concentrated in high-barrier platforms and late-stage clinical advancements.

Investment Summary: The Shift Toward De-risked Assets

The narrative of H2 2025 is one of selective aggression. Investors concentrated capital into “mega-seed” rounds for platforms with high technical barriers while demanding clear exit pathways for late-stage investments.

• Q3 Capital Concentration:The third quarter was defined by extreme capital density in select assets. Outlier valuations were seen in early-stage firms like Accuredit Gene (US$ 75M Series A) and VelaVigo (US$ 60M Pre-Series A+), signaling a “mega-seed” trend for veteran-led platforms.
• Q4 Market Normalization:Activity shifted toward established players. The standout deal of the quarter was TJ Biopharma’s US$ 4M (RMB 600M) Series C2, underscoring a preference for companies with late-stage clinical or commercial capabilities.
• The ADC/RDC Multiplier:Antibody-Drug Conjugates (ADCs) remained the primary theme for large-scale deployment (e.g., the US$ 950M LaNova acquisition). Simultaneously, Radiopharmaceuticals (RDCs) showed unique resilience, evidenced by Full-Life Technologies’ US$ 50M Series C.